Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

[1]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[2]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[3]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[4]  M. Nieminen,et al.  Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial , 2004, Circulation.

[5]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[6]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[7]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[8]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[9]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[10]  Salim Yusuf,et al.  Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003, Circulation.

[11]  P. Guéret,et al.  Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. , 2003, Diabetes care.

[12]  C. Solares,et al.  Tachycardia-induced cardiomyopathy. , 2003, The American journal of medicine.

[13]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[14]  B. Massie.  What is the meaning of LIFE? Implications of the Losartan Intervention for Endpoint reduction in hypertension trial for heart failure physicians. , 2002, Journal of cardiac failure.

[15]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[16]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[17]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[18]  Jennifer Y. Liu,et al.  Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.

[19]  G Corrao,et al.  Alcohol and coronary heart disease: a meta-analysis. , 2000, Addiction.

[20]  B. Howard,et al.  Impact of diabetes on cardiac structure and function: the strong heart study. , 2000, Circulation.

[21]  C. Mogensen.  The kidney and hypertension in diabetes mellitus , 1989, Springer US.

[22]  N. Hollenberg.  Ace Inhibition, Angiotensin II Receptor Blockade, and Diabetic Nephropathy , 2000 .

[23]  V. Gopalakrishnan,et al.  Endothelin: emerging role in diabetic vascular complications , 1999, Diabetologia.

[24]  J. Buring,et al.  Light-to-moderate alcohol consumption and the risk of stroke among U.S. male physicians. , 1999, The New England journal of medicine.

[25]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[26]  H. Lithell,et al.  Relation Between Plasma Tumor Necrosis Factor-α and Insulin Sensitivity in Elderly Men With Non–Insulin-Dependent Diabetes Mellitus , 1998 .

[27]  L. Tavazzi,et al.  Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. , 1998, Journal of the American College of Cardiology.

[28]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[29]  R. Brownsey,et al.  Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. , 1997, Cardiovascular research.

[30]  K. Ellenbogen,et al.  Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. , 1997, Journal of the American College of Cardiology.

[31]  S. Harkins,et al.  Baroreflex control of plasma norepinephrine and heart period in healthy subjects and diabetic patients. , 1986, The Journal of clinical investigation.

[32]  M Bobak,et al.  Alcohol and coronary heart disease. , 1985, The New Zealand medical journal.